Alembic Pharmaceuticals rose 1.68% to Rs 522.40 at 09:26 IST on BSE after the company announced that it has received Establishment Inspection Report for its API facility at Karakhadi.
The announcement was made after market hours yesterday, 19 July 2018.Meanwhile, the S&P BSE Sensex was up 64.97 points, or 0.18% to 36,416.20.
On the BSE, 726 shares were traded in the counter so far compared with average daily volumes of 4,254 shares in the past two weeks. The stock had hit a high of Rs 526.75 and a low of Rs 517.15 so far during the day. The stock hit a 52-week high of Rs 588 on 15 February 2018. The stock hit a 52-week low of Rs 412.40 on 24 May 2018.
Alembic Pharmaceuticals said that the company has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for the inspection carried out by them at API facility at Karakhadi from 14 May 2018 to 18 May 2018. With this, all manufacturing facilities for international markets are FDA compliant.
On a consolidated basis, net profit of Alembic Pharmaceuticals rose 0.81% to Rs 93.79 crore on 15.10% rise in net sales to Rs 853.31 crore in Q4 March 2018 over Q4 March 2017.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content